|Bid||285.55 x 900|
|Ask||288.20 x 800|
|Day's Range||279.46 - 287.86|
|52 Week Range||176.36 - 293.17|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||30.15|
|Earnings Date||Jul 27, 2022 - Aug 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||293.51|
Subscribe to Yahoo Finance Plus to view Fair Value for VRTX
The Dow Jones strengthened in afternoon trading Friday, along with the Nasdaq, which was unfazed by a sell-off in semiconductor stocks.
If you hold on to a promising growth stock for five years, you should expect to accumulate some decent gains over that time. Investing in just the S&P 500 would have resulted in a nearly 60% increase in value -- and that's even after factoring in this year's bearish market. Five years ago, Vertex Pharmaceuticals (NASDAQ: VRTX) was coming off a year when its revenue soared by 65% to $1.7 billion.
Is a recession coming? Ark Invest CEO Cathie Wood thinks that one has already arrived. Economists surveyed by The Wall Street Journal put the odds of a recession over the next 12 months at 44%. Federal Reserve chairman Jerome Powell recently said that a recession is "a possibility," although the Fed is trying to avoid causing one with its interest rate hikes.